KYORIN Pharmaceutical Co., Ltd. Logo

KYORIN Pharmaceutical Co., Ltd.

Researches, develops, and sells a portfolio of ethical, generic, and OTC medicines.

4569 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
千代田区大手町一丁目3番7号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

KYORIN Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and commercialization of medicines. The company's business focuses on several key areas, including the creation of innovative new ethical drugs through its own drug discovery and in-licensing activities. Its portfolio also encompasses generic drugs and over-the-counter (OTC) products, such as the COOL ONE series. The company aims to contribute to public health by developing high-value treatments that meet medical needs. In April 2023, the current entity was formed when KYORIN Holdings, Inc. merged with its wholly-owned subsidiary, KYORIN Pharmaceutical Co., Ltd., and adopted the subsidiary's name.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for KYORIN Pharmaceutical Co., Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-26 07:25
Regulatory News Service
臨時報告書
Japanese 23.5 KB
2025-06-19 08:55
Regulatory News Service
内部統制報告書-第67期(2024/04/01-2025/03/31)
Japanese 27.1 KB
2025-06-19 08:53
Regulatory News Service
確認書
Japanese 8.9 KB
2025-06-19 08:50
Annual Report
有価証券報告書-第67期(2024/04/01-2025/03/31)
Japanese 1.4 MB
2024-11-13 07:27
Regulatory News Service
確認書
Japanese 8.9 KB
2024-11-13 07:24
Interim Report
半期報告書-第67期(2024/04/01-2025/03/31)
Japanese 216.2 KB
2024-06-28 08:30
Regulatory News Service
臨時報告書
Japanese 23.5 KB
2024-06-24 08:53
Regulatory News Service
内部統制報告書-第66期(2023/04/01-2024/03/31)
Japanese 24.3 KB
2024-06-24 08:51
Regulatory News Service
確認書
Japanese 8.9 KB
2024-06-24 08:47
Annual Report
有価証券報告書-第66期(2023/04/01-2024/03/31)
Japanese 1.3 MB
2024-02-14 07:07
Regulatory News Service
確認書
Japanese 8.9 KB
2024-02-14 07:05
Quarterly Report
四半期報告書-第66期第3四半期(2023/10/01-2023/12/31)
Japanese 190.9 KB
2023-11-14 07:36
Regulatory News Service
確認書
Japanese 8.2 KB
2023-11-14 07:34
Quarterly Report
四半期報告書-第66期第2四半期(2023/07/01-2023/09/30)
Japanese 189.8 KB
2023-08-09 08:01
Regulatory News Service
確認書
Japanese 8.2 KB

Automate Your Workflow. Get a real-time feed of all KYORIN Pharmaceutical Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for KYORIN Pharmaceutical Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC

Talk to a Data Expert

Have a question? We'll get back to you promptly.